Kymera Therapeutics, Inc.
KYMR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815442
In the last 90 days, Kymera Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 276 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.
Holders of 5% or more of KYMR
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Kymera Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 14.30%11.7M shares | +3.10 ppfrom 11.20% | Feb 8, 20216 filings | May 6, 2026 | SEC |
| Baker Bros. Advisors LP | 13D/A | 10.90%8.68M shares | +1.40 ppfrom 9.50% | Jun 30, 20252 filings | Dec 11, 2025 | SEC |
| Price T Rowe Associates Inc | 13G/A | 10.70%8.87M shares | +2.10 ppfrom 8.60% | Feb 14, 20224 filings | Sep 8, 2026 | SEC |
| T. Rowe Price Investment Management, Inc. | 13G | 6.70%5.46M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| Biotechnology Value Fund L P | 13D/A | 6.30%5.24M shares | −2.20 ppfrom 8.50% | Jan 31, 20223 filings | Jun 26, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 5.40%3.80M shares | – | Jul 17, 20251 filing | Jul 17, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
31 Schedule 13D and 13G filings on Kymera Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Sep 8, 20269:42 AM ET | Price T Rowe Associates Inc | 13G/A | 10.70%8.87M shares | +2.10 ppfrom 8.60% | Aug 31, 2026 | SEC |
| Aug 14, 202610:38 AM ET | Price T Rowe Associates Inc | 13G/A | 8.60%7.11M shares | +1.50 ppfrom 7.10% | Jun 30, 2026 | SEC |
| Aug 13, 20264:42 PM ET | Atlas Venture Fund X, L.P.and 5 others | 13G/A | 2.90%2.38M shares | –Below 5% | Jun 30, 2026 | SEC |
| Jun 26, 20266:43 PM ET | Biotechnology Value Fund L Pand 10 others | 13D/A | 6.30%5.24M shares | −2.20 ppfrom 8.50% | Jun 26, 2026 | SEC |
| May 15, 202610:06 AM ET | T. Rowe Price Investment Management, Inc. | 13G | 6.70%5.46M shares | New | Mar 31, 2026 | SEC |
| May 15, 20267:48 AM ET | Wellington Management Group LLPand 2 others | 13G/A | 4.80%3.89M shares | −0.70 ppfrom 5.50%Below 5% | Mar 31, 2026 | SEC |
| May 6, 202611:23 AM ET | FMR LLCand 1 other | 13G/A | 14.30%11.7M shares | +3.10 ppfrom 11.20% | Mar 31, 2026 | SEC |
| Mar 27, 202610:18 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −8.05 ppfrom 8.05%Below 5% | Mar 13, 2026 | SEC |
| Feb 10, 202611:17 AM ET | Wellington Management Group LLPand 3 others | 13G/A | 5.50%4.41M shares | −2.20 ppfrom 7.70% | Dec 31, 2025 | SEC |
| Jan 8, 20269:09 AM ET | FMR LLCand 1 other | 13G/A | 11.20%8.93M shares | +3.00 ppfrom 8.20% | Dec 31, 2025 | SEC |
| Dec 15, 20256:07 PM ET | Biotechnology Value Fund L Pand 10 others | 13D/A | 8.50%6.87M shares | – | Dec 11, 2025 | SEC |
| Dec 11, 20255:27 PM ET | Baker Bros. Advisors LPand 3 others | 13D/A | 10.90%8.68M shares | +1.40 ppfrom 9.50% | Dec 9, 2025 | SEC |
| Nov 14, 202512:19 PM ET | Price T Rowe Associates Inc | 13G/A | 7.10%5.10M shares | – | Sep 30, 2025 | SEC |
| Nov 5, 202511:40 AM ET | FMR LLCand 1 other | 13G/A | 8.20%5.88M shares | +1.40 ppfrom 6.80% | Sep 30, 2025 | SEC |
| Aug 12, 202510:34 AM ET | Wellington Management Group LLPand 3 others | 13G/A | 7.70%5.37M shares | −1.50 ppfrom 9.20% | Jun 30, 2025 | SEC |
| Jul 17, 20258:12 PM ET | BlackRock, Inc. | 13G/A | 5.40%3.80M shares | – | Jun 30, 2025 | SEC |
| Jun 30, 20258:26 PM ET | Baker Bros. Advisors LPand 3 others | 13D/A | 9.50%6.67M shares | – | Jun 26, 2025 | SEC |
| May 12, 202510:44 AM ET | Wellington Management Group LLPand 3 others | 13G/A | 9.20%6.00M shares | +1.00 ppfrom 8.20% | Mar 31, 2025 | SEC |
| May 12, 202510:36 AM ET | FMR LLCand 1 other | 13G/A | 6.80%4.41M shares | – | Mar 31, 2025 | SEC |
| Apr 30, 202511:12 AM ET | Vanguard Group Inc | 13G/A | 8.05%5.23M shares | – | Mar 31, 2025 | SEC |
| Feb 10, 202510:25 AM ET | Wellington Management Group LLPand 3 others | 13G/A | 8.20%5.31M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 2022 | Redmile Group, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Price T Rowe Associates Inc | 13GOld format | – | New | – | SEC |
| Feb 11, 2022 | Atlas Venture Fund X, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Vanguard Group Inc | 13GOld format | – | New | – | SEC |
| Feb 9, 2022 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 4, 2022 | Wellington Management Group LLP | 13GOld format | – | New | – | SEC |
| Jan 31, 2022 | Biotechnology Value Fund L P | 13D/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Atlas Venture Fund X, L.P. | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Redmile Group, LLC | 13GOld format | – | New | – | SEC |
| Feb 8, 2021 | FMR LLC | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Kymera Therapeutics, Inc. shares.
No Form 144 notices for Kymera Therapeutics, Inc. are on file.